Fig. 2

Famotidine contributed to GSDME activation and IL-18 release. A BGC-823 and (B) AGS cells were treated with or without famotidine for 72 h, mRNA levels of indicated genes were analyzed by RT-qPCR. Data represented the mean ± s.d. of three independent experiments and were analyzed by t test for significance versus Control group (0 μm), ***P < 0.001, **P < 0.01, *P < 0.05 versus control group(0 μm). NS: no significance. C BGC-823 and AGS cells were treated as indicated and at 72 h post-treatment, cells were harvested to extract total proteins. The SDS-PAGE and immunoblotting were performed to detect indicated proteins, and relative protein expression were quantified and analyzed by t test. Data represented the mean ± s.d. of three independent experiments and were analyzed by t test for significance versus Control group (0 μm), ***P < 0.001, **P < 0.01, *P < 0.05 versus control group(0 μm), the gels/blots and quantitative were processed in parallel. D BGC-823 and AGS cells were treated as described in C, the supernatant was collected. The level of IL-18 (left panel) and IL-1β (right panel) were measured by Elisa according to the instruction, respectively. Data represent the mean ± s.d. of three independent experiments and were analyzed by t test for significance versus Control group (0 μm), **P < 0.01 versus control group(0 μm)